Mind Imaging Competitors

Mayo Clinic has expanded and changed in many ways, but our values remain true to the vision of our founders. Our primary value – The needs of the patient come first – guides our plans and decisions as we create the future of health care. Join us and you'll find a culture of teamwork, professionalism and mutual respect, and most importantly, a life-changing career. Mayo Clinic was founded in Rochester, Minnesota by brothers Dr. William James Mayo and Dr. Charles Horace Mayo. More than 100 years later, their vision continues to evolve around a single guiding value: "The needs of the patient come first." Today we are the largest integrated, not for-profit medical group practice in the world. We are recognized for high-quality patient care more than any other academic medical center in the nation. These endorsements are very gratifying, but also humbling. They remind us of the tradition that has been entrusted to each one of us, and the legacy of excellence that we uphold every day.

We've hopped over to @google! Follow us there for all the latest from Fitbit.

Wave Neuroscience is a Newport Beach, California-based neurotechnology company founded in 2019 on a simple premise: mental health is brain health, and biomarker-guided neuromodulation can pioneer a new era in brain health treatment. Wave developed MeRT® (Magnetic e-Resonance Therapy), the first FDA-cleared personalized, EEG-guided neuromodulation system for PTSD. Unlike standard approaches cleared for other mental health conditions that apply the same protocol to every patient, MeRT begins with a quantitative EEG to map each patient’s unique brain activity, then delivers precisely derived transcranial magnetic stimulation (TMS) tailored to their individual neurophysiology. Wave's pivotal clinical trial demonstrated a 52% average reduction in PTSD symptoms — a superior outcome compared to antidepressants, trauma-focused talk therapy, and other FDA-cleared neuromodulation protocols. At the end of treatment, 68% of active participants classified as "in remission" by falling below the clinical threshold for PTSD.(1) Wave's mission is to move mental healthcare from subjective symptom management to measurable, personalized, effective intervention. (1) Pivotal Trial: Multi-site, double-blind, sham-controlled randomized trial (n=158). Primary endpoint: change in PTSD Checklist for DSM-5 (PCL-5) scores. All results favor active MeRT treatment group. Source: U.S. Food and Drug Administration. 510(k) Summary: MeRT® System (K260402). June 3, 2026.